Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
The compound is currently in Phase 3 evaluation under the TRIUMPH program, which spans registrational trials in obesity, obstructive sleep apnea, and knee osteoarthritis (PMID 41090431)
[DOI] [PubMed] [Google Scholar] 79.Besch G., Perrotti A., Salomon du Mont L., et al
While Retatrutide Weight Loss Treatment is not yet officially available in Mumbai or India, ongoing research and regulatory progress suggest it may become an important option in the future
And insurance providers may not cover the cost of off-label medications
Currently, Long-Acting GLP-1 Agonists Occupies the Largest Share of the GLP-1 Market In terms of the type of GLP-1 agonists drugs, the market is segmented into short-acting GLP-1 agonist and long-acting GLP-1 agonist
Back Jin, T (May 2023) 'Tirzepatide, a new class of incretin-based drug for diabetes' , Obesity Medicine , 39, 1000483
US$ 22.93
US$ 23.54
US$ 29.20
US$ 20.81
US$ 21.25
US$ 26.94
US$ 24.41
